Business Travel and Behavioral and Mental Health

Fly-in-fly-out work: A review of the impact of an extreme form of work-related travel on mental health

Large distances between work and home require many workers to stay away from home for work over extended periods. An extreme case of such work is fly-in-fly-out (FIFO) work. FIFO work requires workers to stay, over a fixed number of days or weeks, in remote employer-arranged accommodation. Given the disruptive nature of this work arrangement, it is important to develop an understanding of its implications for worker mental health. Based on a systematic review, we identify mostly negative mental health implications of FIFO work and propose an integrative model that brings together FIFO work's key features: the simultaneous fracturing and blending of personal and work lives. The model can guide future research. For example, we suggest that researchers investigate how FIFO workers and other work-related travelers experience fracturing and blending, and how they manage the frequent fluctuation between these two extremes.

Plain language summary

Fly-in-fly-out work represents a specific and extreme case of work-related travel in which workers are housed by employers and have fixed schedules that prescribe blocks of time at work followed by blocks of time at home, alongside other rules. This paper provides an overview of the literature regarding the mental health implications of FIFO work. Moreover, an integrative model of FIFO work is proposed that brings together its key defining attributes: the simultaneous fracturing and blending of personal and work lives, which FIFO workers, and by extension other work-related travellers, experience. The model identifies the key attributes of this type of work arrangement that shape fracturing namely the commute (i.e., duration, mode, distance) and rosters (i.e., length and ratio of time on and off) and blending experiences, namely accommodation (i.e., type and quality), extent to which autonomy is limited (i.e., via choice in food, activities, scheduling) and social isolation. While developed for an extreme, highly standardized, and specific case of work-related travel, the model may also be useful in research focused on work related travel more broadly,

From Euphoria to Dysphoria -Why do Cricketers Suffer from High Rates of Depression?

Cricketers suffer from higher rates of depression than both the general public and other sportsmen, as evidenced by the high suicide rates amongst retired test cricketers compared with age-matched controls. This is likely due to a complex array of psychosocial factors including the nature of sportsmen that play cricket, the unique nature of the sport, the duration of matches and hence the time away from support networks and the social situation of cricketers in the pre-professional era.

Jet-Lag Countermeasures Used by International Business Travelers

INTRODUCTION: Research has highlighted the significant impact that jet lag can have upon performance, health, and safety. International business travelers have an important role in economic growth; however, there is a lack of research investigating jet lag and jet-lag management in international business travelers. This study aimed to investigate international business travelers use of jet-lag countermeasures. METHODS: International business travelers from Australia (N = 107) participated in a survey examining use of jet-lag countermeasures (pharmacological and nonpharmacological). Chi-squared tests were conducted examining the association between duration of stay and traveling experience on jet-lag countermeasure use. RESULTS: Most subjects had traveled for business for less than 15 yr and 57% reported taking between 14 trips annually. Durations of stay averaged 10 d (SD 13 d). Nonpharmacological countermeasure use was high. Pharmacological countermeasure use was less common. There were no significant associations between duration of stay and countermeasure implementation. Travel experience was only associated with nonpharmacological countermeasures after arrival home. CONCLUSION: Education programs delivered through businesses would be beneficial for providing information on jet lag, its implications, and recommended countermeasures to travelers. Rigney G, Walters A, Bin YS, Crome E, Vincent GE. Jet-lag countermeasures used by international business travelers. Aerosp Med Hum Perform. 2021; 92(10):825830.

Association Between Business Travel, Health-Related Behaviors, and Adiposity

OBJECTIVE

To evaluate the associations between frequency of business travel and health behaviors and adiposity.

METHODS

Retrospective cross-sectional analysis of de-identified electronic medical records from 795 corporate physical exams.

RESULTS

Business travel frequency demonstrates a curvilinear relationship with body mass index and body composition in men and women, with domestic and international travel. Linear and quadratic term beta coefficients indicate stronger associations between the sum of domestic and international travel and BMI, body fat percentage, and visceral adipose tissue in women than men, after accounting for age, exercise, and sleep. Based on our male sample population, international travel frequency has a greater influence on adiposity than summed (mostly domestic) travel.

CONCLUSIONS

Frequent business travel adversely affects body composition, with differences by gender and type of travel.

Ill-being or well-being? Energising international business travellers

Purpose

The purpose of this qualitative study is to explore well-being experiences of international business travellers (IBTs) and contribute to our understanding of personal and job characteristics as antecedents of ill- or well-being.

Design/methodology/approach

The authors’ insights are based on semi-structured in-depth interviews with 32 IBTs assigned to various destinations ranging from single-country travel to global operation. Participants in this study represent a range of traveller personas (regarding demographics, type of work, travel patterns). Thematic analysis is used to reveal new insights.

Findings

The authors’ analysis revealed trip-load (i.e. workload, control, organisational support) and intensity of travel (i.e. frequency, duration and quality) as job characteristics that sit on an energy stimulation continuum, driving work-related outcomes such as stress and burnout or health and well-being. Energy draining and boosting processes are moderated by cognitive flexibility and behavioural characteristics.

Practical implications

Findings represent a framework for managing IBT well-being via adjustments in job and travel characteristics, plus guidance for training and development to help IBTs self-manage.

Originality/value

The insights within this paper contribute to the conversation around how to enhance well-being for IBTs and frequent flyers. The study intends to offer direction as to which specific job, psychological and behavioural characteristics to focus on, introducing a novel framework for understanding and avoiding serious consequences associated with international mobility such as increased stress, burnout and ill-health.

Effects of Environmental Change on Travelers' Sleep Health: Identifying Risk and Protective Factors

Objective

The aim of this study is to predict the risk and protective factors for the differential effects of the environment on travelers’ sleep health.

Methods

A sample of 505 travelers who stayed overnight in one of 28 hotels completed a sleep quality scale (SQS), a reduced scale of the Morningness/Eveningness questionnaire (rMEQ), and a hotel customer satisfaction questionnaire (H-SCI).

Results

Individuals who are of morning type (p = 0.002), have reduced sleep duration (p = 0.010), and have high sensitivity to the sleep environment (p = 0.000) are most affected by environmental change. Interestingly, business travelers are more affected by sleep disturbances than leisure travelers, travelers who are more satisfied with hotels are less likely to experience insomnia in a new sleep environment (p = 0.000), and insomniacs are more likely to recover from insomnia during a trip (p = 0.000).

Conclusion

Environmental change has an inconsistent impact on the sleep health of different individuals. In a new sleep environment, the possible risk factors for sleep health include (1) being of morning type, (2) reduced sleep duration during trip, (3) sensitivity to the sleep environment, and (4) business stress, while a possible protective factor is satisfaction with the hotel. Possible factors aiding in recovery from home insomnia include (1) being of evening type and (2) higher satisfaction with the hotel.

Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review

BACKGROUND

Tafenoquine is an 8-aminoquinoline anti-malarial drug recently approved as a single-dose (300 mg) therapy for Plasmodium vivax relapse prevention, when co-administered with 3-days of chloroquine or other blood schizonticide. Tafenoquine 200 mg weekly after a loading dose is also approved as travellers' prophylaxis. The development of tafenoquine has been conducted over many years, using various dosing regimens in diverse populations.

METHODS

This review brings together all the preclinical and clinical data concerning tafenoquine central nervous system safety. Data were assembled from published sources. The risk of neuropsychiatric adverse events (NPAEs) with single-dose tafenoquine (300 mg) in combination with chloroquine to achieve P. vivax relapse prevention is particularly examined.

RESULTS

There was no evidence of neurotoxicity with tafenoquine in preclinical animal models. In clinical studies in P. vivax relapse prevention, nervous system adverse events, mainly headache and dizziness, occurred in 11.4% (36/317) of patients with tafenoquine (300 mg)/chloroquine versus 10.2% (19/187) with placebo/chloroquine; and in 15.5% (75/483) of patients with tafenoquine/chloroquine versus 13.3% (35/264) with primaquine (15 mg/day for 14 days)/chloroquine. Psychiatric adverse events, mainly insomnia, occurred in 3.8% (12/317) of patients with tafenoquine/chloroquine versus 2.7% (5/187) with placebo/chloroquine; and in 2.9% (14/483) of patients with tafenoquine/chloroquine versus 3.4% (9/264) for primaquine/chloroquine. There were no serious or severe NPAEs observed with tafenoquine (300 mg)/chloroquine in these studies.

CONCLUSIONS

The risk:benefit of single-dose tafenoquine/chloroquine in P. vivax relapse prevention is favourable in the presence of malaria, with a low risk of NPAEs, similar to that seen with chloroquine alone or primaquine/chloroquine.